These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 16061662

  • 1. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
    Yuste L, Montero JC, Esparís-Ogando A, Pandiella A.
    Cancer Res; 2005 Aug 01; 65(15):6801-10. PubMed ID: 16061662
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.
    Exp Cell Res; 2005 Apr 01; 304(2):604-19. PubMed ID: 15748904
    [Abstract] [Full Text] [Related]

  • 3. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D.
    Cancer Res; 2002 Oct 15; 62(20):5703-10. PubMed ID: 12384528
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 5. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
    Friedländer E, Arndt-Jovin DJ, Nagy P, Jovin TM, Szöllosi J, Vereb G.
    Cytometry A; 2005 Oct 01; 67(2):161-71. PubMed ID: 16163699
    [Abstract] [Full Text] [Related]

  • 6. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
    Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM.
    Cancer Res; 2005 Jan 15; 65(2):473-82. PubMed ID: 15695389
    [Abstract] [Full Text] [Related]

  • 7. The neuregulin-I/ErbB signaling system in development and disease.
    Britsch S.
    Adv Anat Embryol Cell Biol; 2007 Jan 15; 190():1-65. PubMed ID: 17432114
    [Abstract] [Full Text] [Related]

  • 8. Expression of ErbB2 enhances radiation-induced NF-kappaB activation.
    Guo G, Wang T, Gao Q, Tamae D, Wong P, Chen T, Chen WC, Shively JE, Wong JY, Li JJ.
    Oncogene; 2004 Jan 15; 23(2):535-45. PubMed ID: 14724581
    [Abstract] [Full Text] [Related]

  • 9. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep 15; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

  • 10. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways.
    Jepson S, Komatsu M, Haq B, Arango ME, Huang D, Carraway CA, Carraway KL.
    Oncogene; 2002 Oct 24; 21(49):7524-32. PubMed ID: 12386815
    [Abstract] [Full Text] [Related]

  • 11. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
    Li Z, Mei Y, Liu X, Zhou M.
    Cell Signal; 2007 Mar 24; 19(3):466-71. PubMed ID: 16978839
    [Abstract] [Full Text] [Related]

  • 12. Neuregulins are concentrated at nerve-muscle synapses and activate ACh-receptor gene expression.
    Jo SA, Zhu X, Marchionni MA, Burden SJ.
    Nature; 1995 Jan 12; 373(6510):158-61. PubMed ID: 7816098
    [Abstract] [Full Text] [Related]

  • 13. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G.
    Immunol Lett; 2006 Apr 15; 104(1-2):146-55. PubMed ID: 16384610
    [Abstract] [Full Text] [Related]

  • 14. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J, Shiry L, Pegram M, Leyland-Jones B.
    Cancer Res; 2006 Jul 15; 66(14):7245-52. PubMed ID: 16849573
    [Abstract] [Full Text] [Related]

  • 15. Development of an autocrine neuregulin signaling loop with malignant transformation of human breast epithelial cells.
    Li Q, Ahmed S, Loeb JA.
    Cancer Res; 2004 Oct 01; 64(19):7078-85. PubMed ID: 15466203
    [Abstract] [Full Text] [Related]

  • 16. Ligands for ErbB-family receptors encoded by a neuregulin-like gene.
    Chang H, Riese DJ, Gilbert W, Stern DF, McMahan UJ.
    Nature; 1997 May 29; 387(6632):509-12. PubMed ID: 9168114
    [Abstract] [Full Text] [Related]

  • 17. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2.
    Longva KE, Pedersen NM, Haslekås C, Stang E, Madshus IH.
    Int J Cancer; 2005 Sep 01; 116(3):359-67. PubMed ID: 15800944
    [Abstract] [Full Text] [Related]

  • 18. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.
    Esparís-Ogando A, Díaz-Rodríguez E, Montero JC, Yuste L, Crespo P, Pandiella A.
    Mol Cell Biol; 2002 Jan 01; 22(1):270-85. PubMed ID: 11739740
    [Abstract] [Full Text] [Related]

  • 19. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.
    Lim SJ, Lopez-Berestein G, Hung MC, Lupu R, Tari AM.
    Oncogene; 2000 Dec 14; 19(54):6271-6. PubMed ID: 11175341
    [Abstract] [Full Text] [Related]

  • 20. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM, Breen K, Rødland MS, Haslekås C, Stang E, Madshus IH.
    Mol Cancer Res; 2009 Feb 14; 7(2):275-84. PubMed ID: 19208749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.